Standout Papers

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Ov... 2021 2026 2022 2024158
  1. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments (2021)
    T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology

Immediate Impact

51 standout
Sub-graph 1 of 23

Citing Papers

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
Targeting KRAS: from metabolic regulation to cancer treatment
2025 Standout
1 intermediate paper

Works of Masaki Shimoji being referenced

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
2021 Standout
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
2015

Author Peers

Author Last Decade Papers Cites
Masaki Shimoji 762 662 418 37 1.1k
Toshiki Takemoto 608 518 366 39 924
Remy B. Verheijen 772 618 519 50 1.3k
Takuro Kometani 589 616 551 43 1.2k
Dana Ghiorghiu 911 794 487 35 1.3k
Gonzalo Recondo 553 616 361 52 1.1k
Ichiro Kawada 659 567 511 54 1.1k
Toshio Fujino 550 407 386 52 935
Qi Li 564 537 525 27 1.0k
Pang‐Dian Fan 667 604 587 25 1.2k
Roberta Caputo 633 773 587 26 1.3k

All Works

Loading papers...

Rankless by CCL
2026